Search
Search Results
-
Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review
Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which...
-
Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of Alzheimer’s disease (AD). Aβ exists as various species, including...
-
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials
Clinical Dementia Rating–Sum of Boxes (CDR–SB) assessments from two Phase 3 studies (ENGAGE and EMERGE) of aducanumab in subjects with early...
-
Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model
BackgroundAducanumab (Adu), which is a human IgG1 monoclonal antibody that targets oligomer and fibril forms of beta-amyloid, has been reported to...
-
-
-
A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease
BackgroundAducanumab is an anti-amyloid-β (Aβ) antibody that achieved reduced amyloid pathology in Alzheimer’s disease (AD) trials; however, it is...
-
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
BackgroundWith the approval of disease-modifying treatments (DMTs) for early Alzheimer’s disease (AD), there is an increased need for efficient and...
-
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial....
-
The Overview of Drugs Used in Alzheimer’s Disease and Their Molecular Targets
Alzheimer’s disease (AD) is a progressive condition in which degeneration of neuronal cells is observed in the brain. There are many drugs approved...
-
The Amyloid Cascade Hypothesis Has to Deliver, Finally
The Alzheimer’s field has been intensively searching for a therapy, especially in the last 30 years, while the number of affected individuals has...
-
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves...
-
Passive immunotherapy for Alzheimer’s disease: challenges & future directions
Passive immunotherapy with specific antibodies targeting Amyloid β (Aβ) peptide or tubulin-associated unit (tau) protein has emerged as a promising...
-
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early...
-
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
The amyloid cascade hypothesis is a useful framework for therapeutic development in Alzheimer’s disease (AD). Amyloid b 1-42 (Aβ) has been the main...
-
Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia
Neurodegenerative dementia can result from multiple underlying abnormalities, including neurotransmitter imbalances, protein aggregation, and other...
-
Learnings about Aβ from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer’s disease immunotherapeutics
Despite ongoing debate, the amyloid β-protein (Aβ) remains the prime therapeutic target for the treatment of Alzheimer’s disease (AD). However,...
-
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
The second year of the COVID-19 pandemic had no adverse effect on the number of new drug approvals by the US Food and Drug Administration (FDA)....
